A new once-a-day pill made by AstraZeneca has the ability to delay breast cancer progression in those in the advanced stages along with ESR1 mutations, according to phase-3 trials conducted by the company recently. Experts say Camizestrant works by exploiting a unique mechanism of action that distinguishes it from other hormonal therapies.